Syra Health (NASDAQ:SYRA) Issues Quarterly Earnings Results

Syra Health (NASDAQ:SYRA – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.11, reports. Syra Health had a negative return on equity of 131.94% and a negative net margin of 54.90%. The business had revenue of $2.56 million during the quarter, compared to the consensus estimate of $2.20 million.

Syra Health Trading Down 14.0%

Shares of NASDAQ SYRA traded down $0.13 during midday trading on Wednesday, reaching $0.80. The company had a trading volume of 46,574 shares, compared to its average volume of 41,524. The business’s 50-day simple moving average is $0.87 and its 200 day simple moving average is $0.53. The stock has a market cap of $11.08 million, a P/E ratio of -1.23 and a beta of 2.91. Syra Health has a 1 year low of $0.06 and a 1 year high of $1.15.

Syra Health Company Profile

(Get Free Report)

Syra Health Corp. is a healthcare technology and services company focused on improving access, delivery and outcomes across the U.S. healthcare system. The company develops solutions for behavioral and mental health, population health management, healthcare education and workforce needs.

Its offerings are designed to support healthcare providers, government agencies, employers and other organizations. Syra Health combines technology, data and professional services to assist with areas such as care coordination, health education, clinical workforce development, behavioral health programs and population health initiatives.

Based in Carmel, Indiana, Syra Health was established in the early 2020s and serves clients in the United States.

Read More

Earnings History for Syra Health (NASDAQ:SYRA)

Receive News & Ratings for Syra Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syra Health and related companies with MarketBeat.com's FREE daily email newsletter.